Termination by Roche without Cause. Prior to exercise of its first Option Right, Roche shall have the right to terminate this Agreement as a whole or on a Collaboration Target-by-Collaboration Target basis, upon one hundred twenty (120) days prior written notice. Following the exercise of its first Option Right, Roche shall have the right to terminate this Agreement at any time as a whole, on a Collaboration Target-by-Collaboration Target basis, on a Program-by-Program basis, or, after First Commercial Sale, upon a country-by-country basis, upon (a) prior to First Commercial Sale of the first Licensed Product for such Collaboration Target or Program, one hundred twenty (120) days prior written notice or (b) after the First Commercial Sale of the first Licensed Product for such Collaboration Target or Program, one hundred eighty (180) days prior written notice. The effective date of termination under this Section 21.2.4 shall be the date one hundred twenty (120) days (or one hundred eighty (180) days as the case may be) after Roche provides such written notice to BPM.
Appears in 3 contracts
Sources: Collaboration and License Agreement (Blueprint Medicines Corp), Collaboration and License Agreement (Blueprint Medicines Corp), Collaboration and License Agreement (Blueprint Medicines Corp)